UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Apathy and Depression in Huntington’s Disease: Distinct Longitudinal Trajectories and Clinical Correlates

The journal of neuropsychiatry and clinical neurosciences, 2023-01, Vol.35 (1), p.69-76

2023

Volltextzugriff (PDF)

Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

Molecular therapy, 2023-01, Vol.31 (1), p.282-299

2023

Volltextzugriff (PDF)

TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31

Human molecular genetics, 2018-08, Vol.27 (16), p.2893-2912

2018

Volltextzugriff (PDF)

Apoptosis and Caspases in Neurodegenerative Diseases

The New England journal of medicine, 2003-04, Vol.348 (14), p.1365-1375

Friedlander, Robert M

2003

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

CNS spectrums, 2021-04, Vol.26 (2), p.164-165

2021

Volltextzugriff (PDF)

Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

The Journal of neuroscience, 2002-03, Vol.22 (5), p.1592-1599

2002

Volltextzugriff (PDF)

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Human molecular genetics, 2018-07, Vol.27 (14), p.2490-2501

2018

Volltextzugriff (PDF)

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

BMJ open, 2022-06, Vol.12 (6), p.e062740-e062740

2022

Volltextzugriff (PDF)

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

EBioMedicine, 2024-05, Vol.103, p.105124, Article 105124

2024

Volltextzugriff (PDF)

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Translational psychiatry, 2013-12, Vol.3 (12), p.e332-e332

2013

Volltextzugriff (PDF)

Cause or compensation?-Altered neuronal Ca 2+ handling in Huntington's disease

CNS neuroscience & therapeutics, 2018-04, Vol.24 (4), p.301-310

2018

Volltextzugriff (PDF)

Immunomodulation – a disease‐modifying avenue for treatment of Huntington's disease?

Journal of neurochemistry, 2016-06, Vol.137 (5), p.670-672

Bjorkqvist, Maria

2016

Volltextzugriff (PDF)

The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin–proteasome system

Human molecular genetics, 2009-08, Vol.18 (16), p.2929-2942

2009

Volltextzugriff (PDF)

Apathy Is Not Depression in Huntington's Disease

The journal of neuropsychiatry and clinical neurosciences, 2009-07, Vol.21 (3), p.266-270

2009

Volltextzugriff (PDF)

Neuropsychiatry Of Movement Disorders

Revista colombiana de psiquiatría, 2017-10, Vol.46 Suppl 1, p.59-68

2017

Volltextzugriff (PDF)

Nabilone Could Treat Chorea and Irritability in Huntington's Disease

The journal of neuropsychiatry and clinical neurosciences, 2006-10, Vol.18 (4), p.553-554

2006

Volltextzugriff (PDF)

Translating Therapies for Huntington's Disease from Genetic Animal Models to Clinical Trials

NeuroRx, 2004-07, Vol.1 (3), p.298-306

2004

Volltextzugriff (PDF)

Effect of 2′-O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells

Artificial DNA, PNA & XNA, 2014-12, Vol.5 (3), p.e1146391-e1146391

2014

Volltextzugriff (PDF)

Medical marijuana in Huntington's disease: report of two cases

Medicine and health, Rhode Island, 2012-06, Vol.95 (6), p.178

2012

Volltextzugriff (PDF)

Good effect of valproate against aggression in Huntington disease. Only two cases reported earlier

Läkartidningen, 2010-12, Vol.107 (48), p.3060-3061

2010

Volltextzugriff (PDF)

Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement

Nihon yakurigaku zasshi, 2014-03, Vol.143 (3), p.144-151

2014

Volltextzugriff (PDF)

Dovenning

Medicine and health, Rhode Island, 2009-12, Vol.92 (12), p.386

Friedman, Joseph H

2009

Volltextzugriff (PDF)

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease

Neurobiology of disease, 2005-06, Vol.19 (1-2), p.47

2005

Volltextzugriff (PDF)

Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease

Chang Gung medical journal, 2011-03, Vol.34 (2), p.135-152

Chen, Chiung-Mei

2011

Volltextzugriff (PDF)

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation

The Journal of biological chemistry, 2002-09, Vol.277 (37), p.33791

2002

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

SprachePortugiesisch

ThemaScience & Technology

KollektionEZB Electronic Journals Library

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(80)
magazinearticle
(1)

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Huntington Disease - Drug Therapy
(57)
Male
(31)
Animals
(27)
Female
(25)
Middle Aged
(24)
Adult
(20)
Disease Models, Animal
(15)
Huntington Disease - Genetics
(14)
Huntington's Disease
(12)
Mice
(12)
Aged
(10)
Huntington Disease - Complications
(10)
Huntingtons Disease
(9)
Clinical Trials As Topic
(8)
Huntington Disease - Metabolism
(8)
Huntington Disease - Pathology
(8)
Huntington Disease - Psychology
(8)
Antipsychotic Agents - Therapeutic Use
(7)
Review
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Apathy and Depression in Huntington’s Disease: Distinct Longitudinal Trajectories and Clinical Correlates

Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31

Apoptosis and Caspases in Neurodegenerative Diseases

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Cause or compensation?-Altered neuronal Ca 2+ handling in Huntington's disease

Immunomodulation – a disease‐modifying avenue for treatment of Huntington's disease?

The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin–proteasome system

Apathy Is Not Depression in Huntington's Disease

Neuropsychiatry Of Movement Disorders

Nabilone Could Treat Chorea and Irritability in Huntington's Disease

Translating Therapies for Huntington's Disease from Genetic Animal Models to Clinical Trials

Effect of 2′-O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells

Medical marijuana in Huntington's disease: report of two cases

Good effect of valproate against aggression in Huntington disease. Only two cases reported earlier

Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement

Dovenning

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease

Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation

Aktive Filter

Suchergebnisse filtern